Keyphrases
Resection
100%
Osteopontin
100%
Cholangiocarcinoma
100%
Poor Survival
100%
Liver Surgery
36%
Serum Levels
27%
Curative Treatment
18%
Healthy Controls
18%
Patient Benefit
18%
Prognostic Biomarker
18%
Tumor Resection
18%
Treatment Options
9%
Clinical Data
9%
Immunohistochemistry
9%
Enzyme-linked Immunosorbent Assay (ELISA)
9%
Operative
9%
Surgical Treatment
9%
Healthy Individuals
9%
Inflammation
9%
Serum Concentration
9%
Postoperative Survival
9%
Primary Sclerosing Cholangitis
9%
Tumor Samples
9%
Expression Level
9%
Tumor Stroma
9%
Stratification Strategy
9%
Lay Summary
9%
Tumor Cells
9%
Metabolic Disorders
9%
Diagnostic Biomarker
9%
Treatment Decisions
9%
Osteopontin Expression
9%
Human Disease
9%
Preoperative Treatment
9%
Surface Glycoprotein
9%
Phosphoprotein
9%
Biliary Cancer
9%
Glyco
9%
Multiple Persons
9%
Quantitative Reverse Transcriptase PCR
9%
Primary Hepatic Tumor
9%
INIS
levels
100%
patients
100%
surgery
54%
liver
45%
tumors
36%
cancer
18%
humans
18%
control
18%
biological markers
18%
concentration
18%
diseases
9%
data
9%
mortality
9%
comparative evaluations
9%
malignancies
9%
inflammation
9%
enzymes
9%
pcr
9%
elevation
9%
stratification
9%
glycoproteins
9%
tumor cells
9%
phosphoproteins
9%
Medicine and Dentistry
Cholangiocarcinoma
100%
Osteopontin
100%
Liver Surgery
36%
Neoplasm
18%
Cancer Surgery
18%
Biological Marker
18%
Immunohistochemistry
9%
Stroma
9%
Enzyme Linked Immunosorbent Assay
9%
Malignant Neoplasm
9%
Glycoprotein
9%
Quantitative Reverse Transcription Polymerase Chain Reaction
9%
Cancer
9%
Bile Duct Cancer
9%
Tumor Cell
9%
Upregulation
9%
Preoperative Treatment
9%
Primary Sclerosing Cholangitis
9%
Metabolic Disorder
9%
Phosphoprotein
9%
Diseases
9%
Pharmacology, Toxicology and Pharmaceutical Science
Osteopontin
100%
Bile Duct Carcinoma
100%
Neoplasm
45%
Biological Marker
18%
Inflammation
9%
Enzyme-Linked Immunosorbent Assay
9%
Malignant Neoplasm
9%
Glycoprotein
9%
RNA Directed DNA Polymerase
9%
Primary Sclerosing Cholangitis
9%
Phosphoprotein
9%
Bile Duct Cancer
9%
Diseases
9%